Advertisement

Topics

Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review

06:24 EDT 16 Apr 2019 | Pharmafile

The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues arising from heart, blood vessel and immune-mediated conditions, some of which were fatal.

While the agency assesses the situation, it announced temporary advice that the drug “should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies or where other disease-modifying therapies cannot be used.

read more

Original Article: Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review

NEXT ARTICLE

More From BioPortfolio on "Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...